Acadia Pharmaceuticals operates in a threat landscape where the stakes aren't abstract - they're patient safety, proprietary research data, and regulatory compliance across a global biopharma footprint. Founded in 1993, the company focuses on neuroscience therapeutics for underserved neurological disorders and rare diseases, with operations spanning North America and Europe. Their pipeline has produced first-in-class approvals: NUPLAZID®, the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE®, the first therapy approved for Rett syndrome.
For a security team, that means protecting pharmaceutical IP, clinical trial data, manufacturing systems, and the personal health information of vulnerable patient populations. The attack surface is broad - phishing campaigns targeting researchers, supply chain risk in drug manufacturing, and the regulatory exposure that comes with operating across multiple jurisdictions. Expect to work across IT and OT environments, interfacing with GxP-validated systems where downtime isn't just inconvenient but potentially dangerous.
The company's stated culture is urgency-driven, rooted in the reality that patients with few treatment options are waiting. That ethos translates to a security posture that can't afford to be academic - you'll need to move fast, understand the specific risks of a biopharma operating environment, and build defenses that hold up under both regulatory scrutiny and real-world adversary pressure.
